The European Organization for Research and Treatment of Cancer (EORTC) Qualtty-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24

Cancer

Volumn 107, Issue 8, 2006, Pages 1812-1822

  Greimel, Elfriede R ^a   Vlasic, Karin Kuljanic ^b   Waldenstrom, Ann Charlotte ^c   Duric, Vlatka M ^d   Jensen, Pernille T ^e   Singer, Susanne ^f   Chie, Weichu ^g   Nordin, Andy ^h   Radisic, Vesna Bjelic ^a   Wydra, Dariusz ⁱ  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b KBC RIJEKA   (Croatia)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF SYDNEY   (Australia)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Cervical cancer; European Organization for Research and Treatment of Cancer; Patient reported outcome; Quality of life; Questionnaire development; Reliability; Validity

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BODY IMAGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CRONBACH ALPHA COEFFICIENT; DISCRIMINANT VALIDITY; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RADICAL HYSTERECTOMY; RELIABILITY; SEXUAL FUNCTION; SYMPTOM; UTERINE CERVIX CANCER; VAGINA; VALIDATION STUDY; VALIDITY;

ADULT; AGED; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; UTERINE CERVICAL NEOPLASMS;

EID: 33750077278     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22217     Document Type: Article

References (19)

1. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J. 2003;9:348-359.
2. Gusberg SB, Runowiczl CD. Gynecologic cancers. In: Holleb AI, Fink DJ, Murphy GP, editors. Textbook of Clinical Oncology. Atlanta: American Cancer Society, 1991;481-485.
3. Keys H, Gibbons SK. Optimal management of locally advanced cervical carcinoma. J Natl Cancer Inst Monogr. 1996; 89-92.
4. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;385:781-786.
5. Buda A, Fossati R, Colombo N, et al. Randomized trail of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAPO1 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol. 2005;23:4137-4146.
6. Long HJ 3rdI, Bundy BN, Grendys EC Jr., et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:4626-4633.
7. Monk BJ, Huang HQ, Cella D, et al. Quality of life outcomes from a randomized Phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:1-7.
8. Aaronson NK, Ahmedzai S, Bergman B, et al., for the EORTC Study Group on Quality of Life. The EORTC QLQ-C30. A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-375.
9. Sprangers MAG, Cull A, Groenvold M, et al. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. Qual Life Res. 1998;7:291-300.
10. Blazeby J, Sprangers M, Cull A, et al. EORTC Quality of Life Group Guidelines for Developing Questionnaire Modules. 3rd ed. Brussels: EORTC Publications; 2001.
11. Cull A, Sprangers M, Bjordal K, et al. EORTC Quality of Life Group Translation Procedure. 2nd ed. Brussels: EORTC Publications; 2002.
12. Schwab DR Construct validity in organization behavior. In: Staw BM, Cummings LL, editors. Research in Organizational Behaviour. Greenwich: JAI Press, 1980:3-43.
13. Fayers PM, Machin D. Multi-item scales. In: Payers PM, Machin D, editors. Quality of Life. Assessment, Analysis and Interpretation. West Sussex: John Wiley & Sons Ltd.; 2000:72-90.
14. Cohen J. Statistical Power Analysis for the Behavioral Sciences, revised ed. New York Academic Press; 1977.
15. Calhoun EA, Fishman DA, Lurain JR, et al. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol. 2004;93:164-169.
16. Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO Stage 1B carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1995;32:1289-1300.
17. Portenoy RK, Thaler H, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A:1326-1336.
18. Steineck G, Bergmark K, Henningsohn L, et al. Symptom documentation in cancer survivors as a basis for therapy modifications. Acta Oncol. 2002;41:244-252.
19. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: EORTC Publications; 2001.